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Regulatory and ethics review of clinical trial protocols is an 
important mechanism to ensure safe and ethical research on human 
participants. Such review processes are integral to the development 
of any new tuberculosis (TB) vaccine. Long delays in approval times 
may increase costs, complicate operational planning by sponsors 
and researchers, and lead to frustration and distrust in the system.1 
Protracted regulatory processes can delay the development of critical 
new drugs and vaccines for high priority diseases such as TB and 
HIV.2 Furthermore, lengthy delays in the approval of clinical trials 
might create the perception that a particular research environment is 
not conducive to investigational product development, with the risk 
that sponsors might choose to conduct the trials elsewhere.
Clinical trials of investigational products, including new candidate 
TB vaccines, must be pre-approved by a regulatory organisation and 
at least one human research ethics committee (HREC) in most parts 
of the world. The statutory regulatory organisation in South Africa 
(SA) is the Medicines Control Council (MCC).3
The South African Tuberculosis Vaccine Initiative (SATVI) is 
an academic research unit within the University of Cape Town 
(UCT) that has been involved in clinical TB research for over 10 
years.4 SATVI has conducted 18 registration-standard vaccine trials, 
including clinical trials of Bacille Calmette-Guérin (BCG) vaccine 
and 5 different novel TB vaccine candidates. These studies have 
contributed to answering critical questions in novel TB vaccine 
development, including methods to measure the mycobacterial 
immune response and immune correlates of risk and protection 
against TB.5-7 As a result of this work, the SATVI clinical research 
site in Worcester, Western Cape Province, is widely regarded as the 
leading TB vaccine research site in the world.4
The objective of this study was to quantify our experience of the 
time taken to achieve regulatory and ethics approval for TB vaccine 
trials as a reflection of the SA research regulatory environment for 
TB vaccine research.
Methods
We determined the length of time for regulatory and ethics approval 
for all TB vaccine trials conducted at SATVI between 2004 and 2012 
on the part of both the MCC and UCT Faculty of Health Sciences 
HREC. All applications were submitted simultaneously to both the 
MCC and HREC.
Approval time was defined as the time between date of protocol 
submission and the date on the letter confirming approval. In the 
case of the MCC, applications were delivered via courier to the MCC 
offices in Pretoria, and the date of receipt by the MCC was used as 
the submission date. Applications submitted to the UCT HREC were 
hand-delivered, and the date of delivery was used as the submission 
date. The MCC and HREC stipulate deadlines for applications prior 
to each committee meeting, and all applications met those deadlines.
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Background. Tuberculosis (TB) vaccine trials in South Africa must be approved by the Medicines Control Council (MCC) and by a human 
research ethics committee (HREC). Delays in regulatory and ethical approval may affect operational and budget planning and clinical 
development of the product.
Aim. Our aim was to analyse the time to regulatory and ethical approval for TB vaccine trials conducted by the South African Tuberculosis 
Vaccine Initiative (SATVI) and to evaluate factors that influence time to final approval.
Method. Sixteen new TB vaccine clinical trials conducted by SATVI between 2004 and 2012 on infants, children, and adults were included. The 
period between submission and final approval was determined for protocols submitted to the MCC and the University of Cape Town HREC.
Results. Median approval time following first submission to the MCC was 122 days (IQR 112 - 168; range 71 - 350), and for protocol amendments 
103 days (interquartile range (IQR) 76 - 141; range 23 - 191; n=30). Median time following first submission for HREC approval was 60 days (IQR 
33 - 81; range 18 - 125), and for amendments 6 days (IQR 4 - 13; range 1 - 37; n=30). There was no significant difference in approval time by trial 
phase, year of submission, revisions required, study population, sample size, or whether a clinical research organisation (CRO) was used.
Conclusion. The time needed for regulatory and ethics approval was highly variable, but MCC approval for first submissions took twice as 
long as HREC approval and was the primary determinant of time to final approval. National regulatory capacity should be strengthened to 
facilitate the conduct of new TB vaccine trials in this country with its high burden of TB.
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The regulatory and ethics submissions of all TB vaccine trial 
protocols conducted by SATVI since its first phase 1 trial of a novel 
TB vaccine in 2004 were included in this analysis. Data recorded 
for each protocol submission included whether this was a first 
application or a protocol amendment, the sponsor of the trial, the 
principal investigator (PI), phase of trial (I, II, III or IV), and the 
year and month of submission. Study population characteristics 
included the sample size and age group (infants, adolescents, adults). 
In certain instances, the application was submitted by SATVI in 
co-operation with the sponsor, and in other cases with the assistance 
of a clinical research organisation (CRO) in co-operation with SATVI 
and the sponsor. If the regulatory body or HREC requested a revised 
submission or further information before final approval, the number 
of protocol revisions required was recorded. In addition to the year of 
submission, approval time was compared before and after December 
2008 to detect possible trends over time.
Data were analysed using Stata version 11 (Datacorp 2011). 
For MCC and HREC applications, median approval times were 
determined, with interquartile ranges (IQR) and minimum-
maximum ranges. Data were stratified according to review body 
(MCC or HREC) and whether this was a first or amendment 
protocol submission. A Kruskal-Wallis test was used for non-
parametric data to compare approval times between MCC and 
HREC, and to determine whether approval time was affected by 
trial phase, year of submission, month of submission, revisions 
required, age of study population, sample size, or whether a CRO 
was used. Statistical significance was defined as a probability level 
of ≤0.05.
Results
A total of 92 applications were submitted to the MCC and HREC for 
16 TB vaccine trial protocols. Of these, 32 were for first applications 
(16 to MCC and 16 to HREC) and 60 (30 each to MCC and HREC) 
were for subsequent protocol amendments.
Median approval time for first submission to MCC was 122 days 
(IQR 112 - 168; range 71 - 350) (Figs 1 and 2). Approval time for 
amendment submissions to the MCC was shorter than for first 
submissions (median 103 days; IQR 76 - 141, range 23 - 191), but 
this difference was not statistically significant (p=0.1). Two (12%) of 
first submissions received MCC approval within 3 months, 6 (38%) 
between 3 and 4 months, 3 (19%) between 4 and 5 months, and 5 
(31%) longer than 5 months. Three (10%) of amendment submissions 
received MCC approval within 3 months, 18 (60%) between 3 and 4 
months, and 9 (30%) longer than 4 months.
Median approval time for HREC first submissions was 60 days 
(IQR 33 - 81; range 18 - 125). For amendment submissions to HREC, 
this time was shorter (median 6 days; IQR 4 - 13; range 1 - 37; 
p<0.001) (Fig. 1). Four (25%) first submissions were approved by 
HREC within 1 month, 5 (31%) between 1 and 2 months, 5 (31%) 
between 2 and 3 months, and 2 (13%) between 3 and 4 months. For 
amendments, HREC approval was received in less than 1 month for 
28 (93%) submissions, and within 1 - 2 months in 2 (7%) cases.
Median approval times for first and amendment submissions to 
the MCC were greater than for HREC (p=0.001) (Fig. 1). The median 
difference between MCC and HREC approval times was 69 days 
(IQR 62 - 86) for first submissions and 82 days (IQR 70 -138) for 
amendment submissions (Fig. 2).
There were no differences in approval time by clinical trial phase, year 
of submission, calendar month of submission, submission before or after 
December 2008, sponsor, PI, age of study population, sample size, or 
whether a clinical research organisation (CRO) was used, for either MCC 
or HREC submissions (Tables 1 and 2).
Of applications submitted to the MCC, 11/16 (68%) first 
submissions and 6/30 (20%) amendment submissions required 
revision or additional information before final approval. The number 
of resubmissions required did not affect approval times by the MCC 
for first or amendment submissions. Thirteen (81%) first HREC 
submissions and 1 (3%) amendment submission required revision 
or additional information. HREC approval time for first submissions 
was not greater for submissions that required revision.
Three trials took longer than 6 months for initial approval (Table 
2; Fig. 2). In all 3 cases, HREC approval had been given in less than 
2 months. The reason for the longer MCC approval times for these 
particular trials was not known.
Discussion
We have described time to approval of TB vaccine trials by regulatory 
and ethics authorities and analysed the factors that influenced these 
approval times. MCC approval for first protocol submissions took 
twice as long as HREC approval and was the primary determinant 
of total time to final approval. There was considerable variability and 
unpredictability in the time required for the MCC approval process, 
which in the worst case took 12 months. HREC approved protocol 
Fig. 1. Box-plot of approval times by first submissions and amendment 
submissions, and by regulatory body. MCC = Medicines Control Council of 
South Africa. HREC = University of Cape Town Human Health Sciences 
Faculty Research Ethics Committee.
Fig. 2. Time to approval for first submissions per individual trial. 
Total time to final approval is shown, as well as individual times for 
MCC and HREC. MCC and HREC approval submissions were made 
simultaneously.
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amendments significantly more quickly than first submissions, 
but amendment approval time for the MCC was similar to first 
submissions.
To our knowledge, this is the first published analysis of regulatory 
approval times in the SA context for vaccine clinical trials. The South 
African Clinical Research Association (SACRA) has called for an 
online poll of research organisations to collect such data for all types 
of clinical trials on a wider scale, but these data have not yet been 
published.8
Time to approval by regulatory and ethics bodies may be 
affected by protocol factors, or by the capacity of the body to 
review and process the application. Our data suggest that approval 
time by the MCC is not significantly influenced by the complexity 
or safety risk associated with a particular protocol, such as the 
phase of trial, participant age group or sample size. The lack of 
correlation between approval time and protocol submissions 
that required clarification or resubmission is also noteworthy. It 
is likely, therefore, that capacity and administrative limitations 
are major drivers in approval delays by the MCC. The MCC has 
undergone structural changes and is committed to improving its 
systems and processes;3 although, in our experience, the trend in 
approval times did not improve over the 8-year period represented 
by our data.
Time for approval of amendments was significantly shorter for 
the HREC than for the MCC. Amendments typically involve specific 
targeted changes to a protocol and do not require a full review of 
a protocol that has been submitted previously; this may be an area 
where the MCC could develop more efficient mechanisms.
Predictability and transparency of the review process is a key 
issue in regulatory and ethics approval, given that there was up to a 
five-fold variation in MCC approval times. Unpredictability of the 
approval process makes planning difficult for researchers and creates 
sponsor anxiety in the context of deadlines for grant funding or 
product development milestones. Greater transparency in the review 
process and a willingness to engage with investigators would improve 
stakeholder perceptions and create more confidence in the regulatory 
review system. For example, regulatory bodies such as the United 
States Food and Drug Administration (FDA) have made pro-active 
efforts to provide information about its ongoing performance on a 
continual basis, including backlogs in application approvals.9
Issues with regulatory capacity are not unique to SA, although 
approval times in Europe and the USA tend to be shorter. The 
European Union (EU) adopted the Clinical Trials Directive 
(EUCTD) in 2001 to improve the clinical research process.10 The 
directive aimed to streamline approval process for all clinical trials 
by, inter alia, defining the role of central and local research ethics 
committees, allowing parallel and not sequential submissions to 
HREC and a national regulatory authority, and stipulating that 
authorities provide decisions within 60 days. In the United Kingdom 
(UK), a similar reform process for HREC approvals was instituted 
Table 1. Approval time for MCC and HREC for first applications by protocol and submission factors (N=16 each)*
MCC HREC
N Median (IQR) Range (min - max) Median (IQR) Range (min - max)
Overall 16 122 (112 - 168) 71 - 350 60 (33 - 81) 18 - 125
Phase of trial
Phase 1 2 130 (126 - 133) 126 - 133 81 (73 - 88) 73 - 88
Phase 2a 12 116 (108 - 168) 71 - 350 60 (41 - 83) 18 - 125
Phase 2b 2 161 (115 - 206) 115 - 206 28 (25 - 30) 25 - 30
CRO
Yes 12 117 (108 - 152) 71 - 350 54 (28 - 71) 18 - 91
No 4 147 (123 - 213) 112 - 266 89 (59 - 115) 45 - 125
Age of study population†
Infants 7 129 (112 - 206) 105 - 350 60 (25 - 104) 18 - 125
Adolescents 3 111 (93 - 266) 93 - 266 49 (45 - 74) 45 - 74
Adults 6 122 (113 - 133) 71 - 175 63 (36 - 73) 24 - 88
Sample size
<50 9 113 (105 - 126) 71 - 350 59 (36 - 67) 18 - 88
50 - 350 5 133 (129 - 160) 112 - 266 91 (73 - 104) 45 - 125
>1 000 2 161 (115 - 206) 115 - 206 28 (25 - 30) 25 - 30
Year of submission
2004 - 2008 9 118 (111 -175) 71 - 350 49 (25 - 60) 18 - 73
2009 - 2012 7 126 (112 - 160) 93 - 266 88(45 - 104) 30 - 125
Revised resubmission required
Yes 10 131 (111 - 175) 71 - 350 64 (38 - 89)‡ 18 - 125
No 6 117 (112 - 126) 93 - 206 43 (30 - 61) 24 - 73
*N=16 each for MCC and HREC. Approval time is given in days. Median times and interquartile ranges (IQR) are given, as well as range (minimum (min) and maximum (max) times). All p-values 
for differences by sub-category within MCC or HREC were >0.05 and are not shown.
†In trials with mixed study populations, the youngest age group was used for this analysis. 
‡Thirteen first REC submissions required resubmission.
RESEARCH
88  February 2013, Vol. 103, No. 2  SAMJ
by the Central Office for Research Ethics Committees (COREC) in 
2007.11 In practice, these measures are not always effective, and end 
users of the system have expressed concern over inefficiencies.11,12 
Nevertheless, compared with our SA experience, approval times for 
all types of clinical trials in the EU and UK are shorter (reported 
mean first approval times range from 43 to 75 days).10-13 In the 
USA, new products, including vaccine candidates, need to be 
approved as part of the Investigational New Drug approval process 
of the FDA before being approved by ethics committees for testing 
in clinical trials. Reported median approval times for all trials 
are significantly shorter in the USA (15 - 45 days).10 However, 
in other parts of Africa and the developing world, little has been 
published on regulatory approval times. Anecdotal evidence from 
our collaborating TB vaccine trial sites in Uganda and Mozambique 
indicate that approval times are longer – approximately 5 months 
for local and national HREC approval, and an additional 8 - 18 
months for national authority approval (E Wobudeya and J Sacralal, 
2012, personal communications). Therefore, it is noteworthy that 
SA regulatory approval times are appreciably shorter than in other 
developing countries.
This study is limited by a small sample size and therefore we were 
unable to perform meaningful sub-analysis of less common factors 
that might substantially affect approval times. Our analysis does 
create a useful platform for discussion, and invites other research 
sites and organisations to share their experiences. The fact that our 
analysis includes data from a single site and for a single group of 




phase Study population Vaccine type
Sample 














36 Negative Negative 111 49
2006 2a Adults Viral-vectored GMO 
(vaccinia virus)
48 Mixed Mixed 71 67
2006 2a Adults Viral-vectored GMO 
(adenovirus)
40 Negative Negative 175 24
2007 2a Infants and children Viral-vectored GMO 
(vaccinia virus)
168 Negative Negative 350 18
2007 2a Adults Fusion protein sub- unit 
+ adjuvant
45 Negative Mixed 126 59
2008 2b Infants Viral-vectored GMO 
(vaccinia virus)
2 784 Negative Negative 206 25
2008 2a Infants Viral-vectored GMO 
(adenovirus)
54 Negative Negative 105 60
2008 2a Adults Fusion protein sub- unit 
+ adjuvant
40 Negative Negative 113 36
2008 1 Adults Live attenuated 
BCG with isoniazid 
pretreatment
82 Negative Positive 133 73
2009 2a Adolescents Fusion protein sub- unit 
+ adjuvant
60 Negative Mixed 93 74
2009 2b Infants Viral-vectored GMO 
(adenovirus)
4 192† Negative Negative 115 91
2011 1 Adults Fusion protein sub- unit 
+ adjuvant
25 Negative Mixed 126 88




112 Mixed Mixed 112 125
2011 2a Adolescents Fusion protein sub- unit 
+ adjuvant
240 Negative Negative 266 45





2012 2a Mixed adults and 
infants
BCG with novel 
administration device
96 Negative Negative 160 104
GMO = genetically modified organism.
*Total trials: 16. Approval times for first submission are given in days.
†Multi-centre trial.
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investigational products (TB vaccines) is a particular strength, since 
our analysis naturally controls for heterogeneity in research site and 
investigational product.
In conclusion, we found that variability in regulatory and ethics 
approval, particularly by the MCC, is a significant factor in the SA 
clinical trial environment. Prolonged regulatory delays may impede the 
conduct of research in critical areas such as TB, and limit the ability of 
SA researchers to compete in the international arena. We acknowledge 
that the MCC is engaged in a process to optimise the regulatory 
pathway. We recommend that stakeholders in academia, industry and 
government engage in discussion to support the MCC in its planned 
restructuring. Furthermore, we call for state investment and capacity 
building for African regulatory bodies, to facilitate TB vaccine research 
in high TB burden countries where it is most needed.
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